Significance Statement {#s01}
======================

In this manuscript, we present the first evidence that activation of neurotensin receptors in the ventral tegmental area contributes to the acquisition of methamphetamine self-administration and has lasting effects on drug seeking. Our findings support the use of agents targeting the neurotensin system as a potential pharmacological approach to treat methamphetamine addiction.

Introduction {#s5}
============

Methamphetamine (METH) addiction contributes a societal burden by increasing health care costs and crime, decreasing productivity, and ultimately causing loss of human life ([@CIT0028]). Currently, no pharmacotherapy has been approved to treat METH addiction. It is well established that the dopaminergic system plays a central role in the acute and chronic pharmacological effects of the drug. Indeed, an increase in extracellular dopamine levels is a hallmark effect of acute METH intake that is observed in the brain, and after prolonged exposure, this can lead to dysregulation of dopamine synthesis and synaptic transmission ([@CIT0005]; [@CIT0007]). However, the mechanisms contributing to changes in dopamine transmission with prolonged METH use are incompletely understood.

Neurotensin is a peptide synthesized in the brain that is known to modulate dopaminergic transmission and dopamine-mediated behavior ([@CIT0011]). Most actions of neurotensin are mediated by NTS1 and NTS2 receptors, which are widely distributed in the mammalian brain and expressed in the ventral mesencephalon ([@CIT0036]; [@CIT0053]). Neurotensin receptors can be found in dopamine cell bodies and dendrites in the ventral tegmental area (VTA) and the substantia nigra (SN), and in dopamine axon terminals in the nucleus accumbens and the caudate/putamen ([@CIT0033]; [@CIT0031]). Neurotensin can directly excite midbrain dopamine neurons or disinhibit firing by reducing D2 dopamine autoreceptor signaling ([@CIT0018]; [@CIT0035]; [@CIT0048]). At the dopamine neuron terminal, neurotensin receptor signaling also reduces the activity of dopamine D2 autoreceptors ([@CIT0054]). Thus, neurotensin receptor activation facilitates dopamine release by inhibiting D2 autoreceptor function, enhancing midbrain dopamine cell activity and in turn increasing dopamine release in terminal areas ([@CIT0026]; [@CIT0010]). In addition, we recently reported that both acute exposure to neurotensin and repeated METH self-administration depress D2 autoreceptor-mediated currents in VTA and SN dopaminergic neurons ([@CIT0047]; [@CIT0035]), possibly suggesting a synergistic effect of METH and neurotensin on dopamine neurotransmission.

The interaction between the dopamine and neurotensin systems is speculated to modulate the reinforcing effects of psychostimulants ([@CIT0001]). For METH, most of the functional evidence has been provided by neurochemical studies in self-administration models. Indeed, prolonged METH exposure and/or high doses of METH increase neurotensin levels in the striatum, as well as in the VTA and SN ([@CIT0055]; [@CIT0012]; [@CIT0016]). Extracellular neurotensin levels are enhanced and directly correlated to the level of METH exposure during self-administration and, to a lesser extent, to noncontingent METH administration ([@CIT0016], [@CIT0017]). Interestingly, elevation of neurotensin levels in the VTA has been observed in rats self-administering METH, but not in yoked rats receiving equal amounts of i.v. METH ([@CIT0016]). This could potentially contribute to drug-seeking behavior, since neurotensin in the VTA is itself reinforcing, supporting operant self-administration ([@CIT0014]) and affecting intracranial self-stimulation responding ([@CIT0039]). In addition, neurotensin receptor antagonism in the VTA disrupts optogenetic self-stimulation of hypothalamic terminals ([@CIT0023]).

The increase of neurotensin levels in response to METH self-administration combined with the reinforcing properties of neurotensin suggests that the VTA is an important locus for the interaction between endogenous neurotensin and METH. Therefore, we hypothesized that endogenous neurotensin input into the VTA contributes to the reinforcing efficacy of METH during self-administration. To test this, we pharmacologically blocked neurotensin receptors by microinfusing the NTS1/NTS2 receptor antagonist SR142948A into the VTA prior to each of the first 5 days of METH self-administration training. We analyzed the effect of neurotensin receptor blockade on acquisition and stabilization of METH self-administration and METH drug-seeking behavior in mice. In addition, we analyzed the effects of SR142948A treatment on METH-induced psychomotor effects after self-administration.

Materials and Methods {#s6}
=====================

Animals {#s7}
-------

Twenty-four male DBA mice (6--7 weeks old) purchased from Jackson Labs were group housed (3--5 per cage) in polycarbonate boxes with rodent bedding and shredding material. Animals were kept on a 12-/12-hour reverse light-dark cycle (lights off at 9:00 [am]{.smallcaps}) with ad libitum access to food and water. For the pilot study presented in [supplementary Figure 1](#sup1){ref-type="supplementary-material"}, male C57BL/6J mice (n=11) who were food trained on the operant task were tested for the effects of SR142948A microinfusions on METH self-administration. All procedures were approved by the Institutional Animal Care and Use Committee at UT Health San Antonio.

Drugs {#s8}
-----

SR142948A (Sigma), a well characterized nonpeptide neurotensin NTS1/NTS2 receptor antagonist ([@CIT0015]), and METH hydrochloride (generously provided by the NIDA Drug Supply Program) were dissolved in sterile physiological saline (NaCl 0.9%).

Catheter and Cannula Implantation {#s9}
---------------------------------

At least 2 weeks after arrival, mice were implanted with an indwelling catheter in the right jugular vein as previously described ([@CIT0029]; [@CIT0046]). After the catheter was secured, mice were moved to a stereotaxic instrument (Kopf Instruments) for placement of bilateral cannulae (10.0 mm, 26-gauge stainless steel hypodermic tubing). The cannulae were aimed to terminate 1 mm above the VTA: 0.65 mm lateral, 3.0 mm caudal, and 3.6 mm ventral from Bregma ([@CIT0013]). The jugular catheter was flushed daily with 0.02 mL heparinized saline (30 units/mL) beginning 3 to 4 days after catheter placement. Mice were housed individually and were allowed at least 7 days to recover from surgeries. Mice (saline: n=11; SR142948A: n=13) that were successfully implanted with i.v. catheters and VTA bilateral cannulae commenced training for METH self-administration.

Intra-VTA Microinfusions {#s10}
------------------------

Bilateral microinfusions of SR142948A or sterile saline were given 15 minutes before self-administration training sessions for the first 5 days. The amount of SR142948A microinfused was 10 ng/side dissolved in a volume of 100 nL of saline and infused for 10 seconds, based on [@CIT0037] and a preliminary study performed in our laboratory ([supplementary Figure 1](#sup1){ref-type="supplementary-material"}). A flow diagram summarizing the behavioral procedures that follow can be seen in [Figure 1A](#F1){ref-type="fig"}.

![Antagonism of neurotensin receptors in the ventral tegmental area (VTA) delays the acquisition of methamphetamine (METH) self-administration and decreases intake. (A) A timeline depiction of the surgical and behavioral procedures. (B) Compared with controls (n=11), mice microinfused with SR142948A (n=8) in the VTA required more training sessions to reach self-administration criteria. (C) SR142948A-treated mice self-administered a lower number of METH infusions during training and (D) later during maintenance of self-administration. (E) METH intake was reduced in SR142948A-treated mice in both training and fixed ratio 3 (FR3) sessions. Bonferroni *t* test posthoc comparisons: \**P*\<.05, \*\**P*\<.01, and \*\*\**P*\<.001 vs CONTROL.](pyx11701){#F1}

Operant Self-Administration Training {#s11}
------------------------------------

To assess catheter patency, catheters were flushed with sterile saline before each operant session and with heparinized saline after the session. Two-hour operant sessions were conducted daily as previously described ([@CIT0029]; [@CIT0046]). Two nose-poke holes were located on one wall of the modular mouse operant chamber (Lafayette Instruments), and the correct nose poke was illuminated by a dim green light located inside of the hole. During training, responses in the correct nose poke hole were rewarded on a fixed ratio 1 schedule of reinforcement (FR1) for infusions 1 to 8, FR2 for infusions 9 to 14, and FR3 for the remainder of the session. Upon completing the response requirement, the green stimulus light was turned off, a 15-second timeout was initiated, and METH was delivered (0.1 mg/kg/infusion, 12 µL over 2 seconds, accompanied by a sound stimulus of 2 kHz). METH infusion dosage was calculated based on a typical weight of a young adult mouse (28 g) and corrected by actual body weight to obtain intake (mg/kg/session). Responding in both nose pokes holes was recorded during the timeout but was not reinforced. Self-administration was considered acquired when the number of infusions earned was ≥8, and the number of nose pokes in the correct hole represented at least 70% of the total nose pokes. Five mice (saline: n=2; SR142948A: n=3) did not acquire METH self-administration within 21 days and were removed from the study.

Self-Administration Stabilization, Extinction, and Progressive Ratio Procedures {#s12}
-------------------------------------------------------------------------------

After acquisition, the mice were advanced to an FR3 schedule of reinforcement (i.e., maintenance) for 10 days. Mice were then placed on an extinction schedule for 7 days, in which the animals were attached to the i.v. tether, but no infusion or sound cue were delivered during the 2-hour session. This was followed by 1 day on an FR3 cue-induced reinstatement schedule (nose pokes resulted in the sound cue, but not METH infusion). Mice were then returned to an FR3 session of drug self-administration. Finally, mice were placed on 2 days of 5-hour sessions on a progressive ratio schedule, in which the number of nose pokes necessary for an infusion was gradually increased (1, 2, 4, 6, 9, ...) following the procedure described by [@CIT0038].

Locomotor Activity {#s13}
------------------

Basal locomotor activity was assessed in all mice during their habituation to the microinfusion procedure (sham microinfusions). Two days before self-administration started, mice were placed in the locomotor chambers equipped with infrared photocells for 15 minutes (pre-sham). After that, mice were gently held, without restraining, and sham injectors were descended through the cannula guides and kept in place for 1 minute. Locomotor activity was quantified again after sham microinfusion for another 15 minutes (post-sham). On the next 5 days, mice were placed in the locomotor chambers immediately after microinfusion of SR142948A or saline (training days 1--5) for 15 minutes, after which the mice were placed in the self-administration chambers for their daily session. Locomotor activity was quantified again for 15 minutes immediately following self-administration sessions. This procedure was conducted before and after each of the remaining self-administration sessions to monitor METH-induced changes in locomotion.

Cannula Placement Verification {#s14}
------------------------------

At the end of the experiments, 100 nL of fast-green dye (2% in ethanol) was injected through the cannulae. The brains of the mice were collected, sliced into serial 200-μm sections and stored in 4% paraformaldehyde. Locations of the injection sites were determined by visual examination. Two mice infused with SR142948A had incorrectly placed cannulae ([supplementary Figure 2](#sup1){ref-type="supplementary-material"}) and were later included along with saline-infused mice in the control group as their responding was not different from the saline-treated mice ([supplementary Figure 3](#sup1){ref-type="supplementary-material"}). The remainder of the mice had both SR142948A injection sites within the boundaries of the VTA, between 3.00 and 3.30 mm posterior to Bregma, and were included in the experimental group for analysis.

Statistical Analysis {#s15}
--------------------

Data were analyzed using SigmaStat 4.0 statistical suite (Systat Software Inc). The 2-tailed Student's *t* test was used to compare days to acquisition between groups. Two-way ANOVA (repeated measures when allowed) was used to determine interactions between treatment and daily session (treatment x session) and treatment x schedule. For posthoc comparisons after ANOVAs, Bonferroni corrected *t* tests were used. Correlation of METH intake with distance traveled was done using Pearson product moment correlation and the correlation coefficients (r) were then compared using Fisher's Z-transformation. All data are reported as mean±SEM. Statistical values of *P*≤.05 were considered significant.

Results {#s16}
=======

Antagonism of Neurotensin Receptors in the VTA Delays and Decreases METH Self-Administration {#s17}
--------------------------------------------------------------------------------------------

Confirming preliminary observations obtained in a pilot experiment ([supplementary Figure S1](#sup1){ref-type="supplementary-material"}), acquisition of METH self-administration was slower in mice receiving microinfusions of SR142948A. These animals required a larger number of training sessions to meet self-administration criteria (t~17~=3.489, *P*=.002, [Figure 1B](#F1){ref-type="fig"}). SR142948A-treated mice self-administered fewer infusions of METH during training sessions (treatment x session: F~11,187~=5.269, *P*\<.001). Posthoc analysis revealed that the number of infusions in SR142948A-treated mice was significantly lower beginning on day 7 of training ([Figure 1C](#F1){ref-type="fig"}). Following acquisition, mice that previously received SR142948A also earned fewer infusions during the subsequent 10 days of FR3 maintenance (treatment: F~1,153~=6.741, *P*=.019, [Figure 1D](#F1){ref-type="fig"}). These differences were paralleled by decreased average METH intake during both training and maintenance (treatment x schedule: F~2,371~=4.603, *P*\<.011: [Figure 1E](#F1){ref-type="fig"}). Analysis of nose poke behavior showed similar differences between groups, with a higher number of correct responses in control animals during training (treatment x session: F~11,187~=6.939, *P* \< .001: [Supplementary Figure 4A](#sup1){ref-type="supplementary-material"}) and FR3 maintenance sessions (treatment: F~1,153~=7.86, *P*\<.01; [Supplementary Figure 4D](#sup1){ref-type="supplementary-material"}). In addition, mice with SR142948A treatment displayed a slower pattern of self-administration, with a significantly reduced number of bouts and a trend toward fewer infusions per bout ([supplementary Figure 5](#sup1){ref-type="supplementary-material"}).

Antagonism of Neurotensin Receptors in the VTA Decreases METH-Seeking Behavior {#s18}
------------------------------------------------------------------------------

In comparison with the last FR3 session, interruption of METH availability resulted in an increased number of correct nose pokes on the first day of extinction which was significant in control mice but not in SR142948A treated animals (treatment x session: F~7,105~=2.653, *P*=.014; [Figure 2A](#F2){ref-type="fig"}). There was no difference in the number of extinction sessions necessary to decrease the number of responses to \<50% between groups (control: 3.9±0.4 days; SR142948A: 4.7±0.5 days). One animal in each group did not meet criteria for extinction within 7 extinction sessions, and these 2 mice were excluded from further analysis. In both groups, the number of correct side nose pokes increased again during the cue-induced reinstatement session (session: F~1,15~=16.987, *P*\<.001 vs baseline), with a higher number of responses observed in the control group (treatment: F~1,15~=7.146, *P*=.017; [Figure 2A](#F2){ref-type="fig"}). No differences between groups were observed in the number of wrong responses on extinction or cue-induced reinstatement (treatment: F~7,105~=0.086, *P*\<.772 and F~1,15~=1.094, *P*=.312; respectively; [Figure 2B](#F2){ref-type="fig"}).

![Methamphetamine (METH)-seeking behavior is decreased by previous intra-ventral tegmental area (VTA) treatment with SR142948A. (A) Compared with the control group, mice treated with SR142948A exhibited fewer correct side responses on the first day of extinction and in cue-induced reinstatement ("cue-reins."). (B) No differences between groups were found in the number of wrong-side nose pokes during extinction or cue-induced reinstatement. (C, D) In the progressive ratio test ("prog. ratio"), the number of correct-side responses was decreased in SR142948A-treated mice compared with controls, with no difference between groups in the number of wrong-side responses. (E, F) METH intake and the breakpoint were lower in SR142948A-treated mice compared with controls. Control: n=10 and SR142948A: n=7, Bonferroni posthoc comparisons: \**P*\<.05 and \*\**P*\<.01 vs CONTROL; \#\#\# *P*\<.01 vs baseline (BL, last fixed ratio 3 \[FR3\] session).](pyx11702){#F2}

In the progressive ratio test, mice in both groups displayed a significant increase in the number of correct side nose poke responses (treatment x session: F~1,15~=5.442, *P*=.034). However, the number of responses was lower in SR142948A treated mice (*P*=.002; [Figure 2C](#F2){ref-type="fig"}). No differences between groups were detected in the number of wrong nose pokes (treatment: F~1,15~=0.735, *P*=.405; [Figure 2D](#F2){ref-type="fig"}). Consequently, METH intake and the maximum reinforcement ratio completed (break point) by mice treated with SR142948A was lower than that observed in control mice (intake: t~15~=2.11, *P*\<.05; break point: t~15~=2.491, *P*=.024; [Figure 2E--F](#F2){ref-type="fig"}). In addition, METH intake history exhibited a positive correlation with seeking behavior observed in the progressive ratio (r=0.606, *P*=.009) but not with that observed in extinction and cue-reinstatement ([supplementary Figure 6](#sup1){ref-type="supplementary-material"}).

Locomotion Is Not Affected by Intra-VTA Infusion of SR142948A, but by Changes in METH Intake {#s19}
--------------------------------------------------------------------------------------------

Locomotor activity was not affected by sham microinfusion or by 5 days of bilateral intra-VTA microinfusion of SR142948A or saline (treatment: F~1,102~=0.402, *P*=.535; [Figure 3A](#F3){ref-type="fig"}). Similar to the pattern observed in the number of METH infusions, differences in basal activity between groups were detected during the subsequent training (treatment: F~1,102~=6.712, *P*=.019; [Figure 3A1](#F3){ref-type="fig"}), maintenance (treatment: F~1,153~=4.539, *P*=.048; [Figure 3A2](#F3){ref-type="fig"}), and cue-induced reinstatement (treatment: F~1,15~=5.272, *P*=.036; [Figure 3A4](#F3){ref-type="fig"}) sessions, but not during extinction (treatment: F~1,90~=1.092, *P*=.313; [Figure 3A3](#F3){ref-type="fig"}). Subtracting pre-session locomotion from post-session locomotion revealed that the net increase in locomotion was not significantly different between treatments during infusion days (treatment: F~1,68~=2.712, *P*=.118; [Figure 3B](#F3){ref-type="fig"}), but it was significantly lower in SR142848A-treated mice during training sessions 9 to 12 (treatment x session: F~6,102~=2.899, *P*=.012; [Figure 3B1](#F3){ref-type="fig"}). No additional differences between groups were detected in FR3 sessions (treatment: F~1,153~=2.523, *P*=.131; [Figure 3B2](#F3){ref-type="fig"}), extinction sessions (treatment: F~1,90~=1.182, *P*=.294; [Figure 3B3](#F3){ref-type="fig"}), or cue-induced reinstatement (treatment: F~1,15~=1.398, *P*\<.255; [Figure 3B4](#F3){ref-type="fig"}). In both groups, the net increase in locomotion was strongly correlated with the amount of daily METH self-administered (control: r=0.821, *P* \< .001; SR142948A: r=0.773, *P* \< .001; [Figure 4](#F4){ref-type="fig"}), with no statistical difference in the strength of the correlation between the 2 treatment groups (Z=1.3, *P*=.193).

![Effects of intra-ventral tegmental area (VTA) treatment with SR142948A on locomotor activity. (A) Basal locomotor activity was not affected by 5 days of SR142948A or saline microinfusions. Distance traveled before self-administration was overall higher in the control group in training days 6 to 12 (A1), in fixed ratio 3 (FR3) maintenance sessions (A2), and in cue-reinstatement (cue-reins, A4). (B) In the control group, the net increase in locomotion after methamphetamine (METH) self-administration (post-session -- pre-session) was higher compared with SR142948A-treated mice only on training days 9 to 12 (B1). No significant changes between groups were detected in maintenance (B2), extinction sessions (B3), cue-reins, or the last FR3 session (B4). Bonferroni posthoc comparisons: \**P*\<.05, \*\**P*\<.01, and \*\*\**P*\<.001 vs CONTROL.](pyx11703){#F3}

![Neurotensin receptor antagonism in the ventral tegmental area (VTA) does not alter methamphetamine (METH)-induced locomotion. In control (n=11) and SR142948A-treated (n=8) mice, the corresponding net increase in locomotion was directly correlated with the amount of METH intake, with no effect of group. In both cases, the correlation follows a strong positive linear association (*P*\<.001).](pyx11704){#F4}

Discussion {#s20}
==========

Here we show that treatment with a nonselective neurotensin receptor antagonist specifically in the VTA delays the acquisition of METH self-administration and decreases METH intake in mice. The long-lasting effects of SR142948A treatment did not prevent the acquisition of self-administration but did appear to decrease subsequent daily intake and the reinforcing efficacy of METH. The effects of SR142948A treatment on self-administration behavior were not associated with changes in basal locomotor activity or interference with METH psychomotor effects.

Neurotensin Modulation of METH Reinforcement Efficacy in the VTA {#s21}
----------------------------------------------------------------

Previous work has established a link between VTA neurotensin and reinforcement. Activation of neurotensin receptors in the VTA (by neurotensin or neurotensin analogues) is able to sustain self-administration behavior ([@CIT0014]), produces conditioned place preference ([@CIT0042]), and increases locomotor activity ([@CIT0021]; [@CIT0020]). Either acute intra-VTA pretreatment with SR142948A (single infusion, 1 week before) or systemic administration of the selective NTSR1 antagonist SR48692 prevents the induction of amphetamine behavioral sensitization but not its acute psychomotor response ([@CIT0040]; [@CIT0034]). This suggests that antagonism of NTS1 receptors selectively prevents amphetamine-induced sensitization. Previous behavioral work involving METH self-administration has largely focused on terminal regions or on the systemic application of neurotensinergic ligands. Interestingly, systemic administration of SR48692 does not modify METH self-administration in experienced rats ([@CIT0012]; [@CIT0016], [@CIT0017]). Work from our laboratory and others suggests that the selective NTS1 receptor agonist PD149163 reduces METH self-administration and METH drug-seeking behavior ([@CIT0012]; [@CIT0016], [@CIT0017]; [@CIT0046]); however, locomotor deficits may contribute to this effect ([@CIT0052]).

The data in the present study provide the first evidence that endogenous neurotensin in the VTA contributes to the reinforcing efficacy of METH. The infusion of SR142948A bilaterally in the VTA during the first 5 days of training not only delayed the acquisition of METH self-administration but had a long-lasting effect by decreasing intake and drug-seeking behavior. Examination of the number of infusions earned on day 7 and 12 of training (the average day for acquisition of self-administration by control and SR142948A groups, respectively) suggests that both groups were earning similar amounts of METH at acquisition ([Figure 1c](#F1){ref-type="fig"}). Therefore, the time course and onset of METH self-administration in SR142948A-treated mice could suggest that the rewarding effects of METH were effectively blocked during the 5 days of treatment. It is possible that SR142948A-treated mice did not experience the reinforcing effects of METH until training day 6, which may have contributed to decreased METH intake in this group in the subsequent sessions. Interestingly, in 2 mice that received infusions of SR142948A outside the limits of the VTA, the treatment was not effective and behavior resembled the saline mice. This is consistent with the fact that SR142948A infused into the ventral pallidum of cocaine-experienced rats has no effect on cocaine self-administration ([@CIT0051]). Furthermore, since our SR142948A infusions were aimed at the rostral region of the VTA, where a subpopulation of dopamine (DA) neurons predominantly expressing NTS1 receptors is located ([@CIT0056]), the persistent effects on intake observed in our experiments may be related to blockade of METH-induced sensitization through antagonism of the NTS1 receptor subtype ([@CIT0040]; [@CIT0034]). It should, however, be noted that there was no difference in acute locomotor stimulation caused by METH seen between treatment groups ([Figure 4](#F4){ref-type="fig"}) as one might expect if there was a difference in sensitization between the two groups. Collectively, our data and the available literature indicate that endogenous neurotensin input selectively to the VTA contributes to the reinforcing efficacy of METH and supports drug-seeking behavior. However, it is possible that the effect of the neurotensin receptor antagonist is not specific for METH; thus, this effect on decreasing reinforcer intake and efficacy may also be true for other forms of reward ([@CIT0023]).

VTA Neurotensin Does Not Alter the Psychomotor Effects of METH {#s22}
--------------------------------------------------------------

We did not observe an effect of SR142948A infused into the VTA on basal locomotor activity. This corroborates previous reports of a lack of observable motor deficits when SR142948A is administered either into the VTA or systemically ([@CIT0037]; [@CIT0027]; [@CIT0004]). Furthermore, intra-VTA infusion of SR142948A does not block the acute psychomotor response to amphetamine ([@CIT0034]). Our results also show that SR142948A-treated mice gradually develop a lower level of basal hyperlocomotion; however, this finding could be explained by the lower METH intake in this group across sessions. As is shown in our correlation analysis, enhanced locomotor activity exhibits a strong linear relationship with METH intake in both groups. In addition, in all mice, the net increase in locomotion was negligible in sessions when METH was not available (extinction and cue-induced reinstatement). Since there is no difference between treatment groups in the locomotor response (net change in activity) when plotted against METH intake during individual sessions, these data suggest that treatment with SR142948A does not affect the locomotor stimulant properties of METH. Certainly, the lower METH intake in SR142948A-treated mice may have influenced their subsequent locomotor response and drug-seeking behavior (see below). Taken together, we conclude that selective antagonism of neurotensin receptors in the VTA affects the reinforcing efficacy (measured by intake) but not the psychomotor effects of METH self-administration (locomotor output).

Integrative Effects of Neurotensin and METH in the VTA {#s23}
------------------------------------------------------

The VTA contains the cell bodies of dopaminergic neurons that have been heavily implicated in reward and expresses NTS1 and possibly NTS2 receptors ([@CIT0008]; [@CIT0001]; [@CIT0045]). The rewarding and psychostimulant effects of neurotensin in the VTA may be contingent on its capability to elicit an increase in dopamine levels in terminal areas such as the nucleus accumbens ([@CIT0020]; [@CIT0026]). This seems to largely depend on activation of NTS1 receptors in VTA DA neurons and is less likely to involve activation of NTS2 receptors, which are predominantly expressed in astrocytes ([@CIT0026]; [@CIT0056]). In the VTA, neurotensin levels increase in response to METH self-administration, and this is observable as early as 5 days after initial exposure to the drug but is not seen in noncontingent METH-exposed animals ([@CIT0016]).

It is possible that endogenous neurotensin actions in the VTA contribute to increased dopamine levels in accumbens after METH self-administration ([@CIT0024]). Interestingly, neurotensin-evoked dopamine release in the nucleus accumbens is not blocked by systemic administration of either SR142948A or SR48692 ([@CIT0015]); however, co-infusion of SR142948A with neurotensin in the VTA reduces the rise in dopamine at the terminal ([@CIT0025]). Given this, we hypothesize that the decrease in METH self-administration observed in our results may be due, at least in part, to NTS1 receptor blockage in VTA DA neurons interfering with a METH-induced increase of dopamine in the accumbens. Theoretically, this decreased the incentive value of METH infusions, at least during the first days of training, thus delaying the acquisition of METH self-administration (as we observed). Furthermore, METH intake history can influence drug-seeking behavior under certain experimental conditions ([@CIT0057]), and our observations suggest that this is dependent on the availability of METH during the test. Indeed, METH intake history correlated with behavior in a progressive ratio but not during extinction or cue reinstatement, when METH was not available ([supplementary Figure 6](#sup1){ref-type="supplementary-material"}).

Although neurotensin produces multiple cellular effects in the VTA, its interactions with METH are most likely dopaminergic. Acutely, METH and other amphetamines increase extracellular dopamine levels by competing as substrates for uptake through dopamine transporters located on the plasma membrane. These compounds then decrease vesicular dopamine content by acting as substrates at vesicular transporters and/or disrupting vesicular pH gradients and ultimately produce DA efflux into the extracellular space through dopamine transporter reversal ([@CIT0050]). Elevated extracellular dopamine is observed at both axon terminal and somatodendritic areas ([@CIT0009]; [@CIT0019]). In the VTA, acute METH application modulates dopamine neurons such that lower concentrations of METH increase firing activity (through a transporter mechanism), while higher concentrations decrease it in a D2 receptor-dependent manner ([@CIT0003]). Activating neurotensin receptors in the VTA attenuates the inhibitory effects of D2 autoreceptor activation and can produce excitatory effects on VTA dopamine neuron firing activity ([@CIT0048]; [@CIT0035]; [@CIT0049]). METH self-administration is also able to chronically decrease D2 autoreceptor function ([@CIT0047]), and at doses already reached during the initial days of training in our present experiments (0.18--0.42 mg/kg), METH strongly reduces the firing rate of dopamine neurons in vivo ([@CIT0022]). Considering that endogenous neurotensin levels in the VTA increase in response to METH self-administration ([@CIT0016]), it is possible that this is a compensatory mechanism to restore normal dopamine neuron activity. The neurotensin receptor antagonists SR142948A and SR48692 do not have direct effects on dopamine neuron firing or D2 autoreceptor function in the VTA, although SR142948A can reverse one form of neurotensin-induced plasticity ([@CIT0035]).

Previously published and ongoing work indicate multiple alternative cellular and circuit mechanisms of action for neurotensin. Systemic administration of SR142948A or SR48692 increases the number of spontaneously active dopamine neurons in the VTA without affecting their firing properties ([@CIT0015]; [@CIT0044]). Further, prolonged systemic administration of SR48692 decreases the number of spontaneously active dopamine cells in the VTA ([@CIT0044]). Other neurotransmitter systems in the VTA may also be recruited by modulation of local neurotensin receptors. For example, the inhibitory effects of GABA on dopamine neurons, through GABA~B~ receptor activation, are decreased by neurotensin ([@CIT0049]; [@CIT0090]). Neurotensin can also modulate glutamatergic activity in dopaminergic and nondopaminergic neurons in the VTA and affect electrical brain self-stimulation behavior ([@CIT0023]; [@CIT0002]; [@CIT0042]).

The current studies were conducted solely in male mice. Sex differences have previously been reported in the context of dopamine and other neuropeptides such as oxytocin ([@CIT0006]); however, this has not been explored regarding neurotensin. Indeed, a recent report suggests that METH-induced locomotor activity and stereotypy behavior may be enhanced in female compared with male rodents ([@CIT0030]; [@CIT0032]). Further research will be needed to address sex differences in the acquisition of METH self-administration and METH-seeking behavior ([@CIT0041]; [@CIT0043]) and the possible implications of a role for neurotensin in METH self-administration.

CONCLUSION {#s24}
==========

Our data indicate that antagonism of neurotensin receptors in the VTA delays the onset of METH self-administration and produces a lasting decrease in METH intake. Neurotensin receptor activation in the VTA is not required for the psychomotor effects of METH, but rather may contribute to the early adaptations occurring in the VTA during the transition to compulsive METH intake. Our results also indicate that neurotensin receptors in the VTA contribute to the early reinforcing efficacy of METH, thus facilitating METH self-administration. The long-lasting effects of SR142948A treatment imply that neurotensin input into the VTA during initial METH exposure modulates later drug intake and drug-seeking behavior. Further studies will be necessary to fully elucidate the cellular mechanisms accompanying neurotensin receptor activation in the VTA during METH self-administration to determine the utility of manipulating the neurotensin system as a possible treatment for METH addiction.
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Supplementary data are available at *International Journal of Neuropsychopharmacology* online.
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